Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.5682
-0.0198 (-3.37%)
At close: Aug 13, 2025, 4:00 PM
0.5601
-0.0081 (-1.43%)
Pre-market: Aug 14, 2025, 8:58 AM EDT
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 3 or -15.00% compared to the previous year.
Employees
17
Change (1Y)
-3
Growth (1Y)
-15.00%
Revenue / Employee
n/a
Profits / Employee
-$3,988,765
Market Cap
18.86M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RLMD News
- 5 days ago - Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC - GlobeNewsWire
- 14 days ago - Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - GlobeNewsWire
- 4 weeks ago - Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 - GlobeNewsWire
- 5 weeks ago - DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors - GlobeNewsWire
- 2 months ago - Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology - GlobeNewsWire
- 3 months ago - Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire